{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:14:27Z","timestamp":1790615667560,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T00:00:00Z","timestamp":1553212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3272-0","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T14:03:41Z","timestamp":1553263421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation"],"prefix":"10.1186","volume":"20","author":[{"suffix":"III","given":"Clifton O.","family":"Bingham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol L.","family":"Gaich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"DeLozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn D.","family":"Engstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April N.","family":"Naegeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pixy","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,22]]},"reference":[{"issue":"4","key":"3272_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/clpt.2011.325","volume":"91","author":"I Colmegna","year":"2012","unstructured":"Colmegna I, Ohata BR, Menard HA. Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther. 2012;91(4):607\u201320.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"3272_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrd1109","volume":"2","author":"Josef S. Smolen","year":"2003","unstructured":"Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2(6):473\u201388.","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1","key":"3272_CR3","doi-asserted-by":"publisher","first-page":"e000019","DOI":"10.1136\/rmdopen-2014-000019","volume":"1","author":"L Gossec","year":"2015","unstructured":"Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019.","journal-title":"RMD Open"},{"issue":"7","key":"3272_CR4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1136\/annrheumdis-2016-209429","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Collaud Basset S, Boers M, Breedveld F, Edwards CJ, Kvien TK, et al. Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Ann Rheum Dis. 2016;75(7):1268\u201371.","journal-title":"Ann Rheum Dis"},{"key":"3272_CR5","volume-title":"Patient-reported outcome measures: use in medical product development to support labeling claims","author":"Guidance for Industry","year":"2009","unstructured":"Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring: Food and Drug Administration; 2009. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/...\/Guidances\/UCM193282.pdf\n                    \n                  . Accessed 15 Aug 2017"},{"key":"3272_CR6","doi-asserted-by":"publisher","first-page":"935187","DOI":"10.1155\/2012\/935187","volume":"2012","author":"J Amaya-Amaya","year":"2012","unstructured":"Amaya-Amaya J, Botello-Corzo D, Calixto OJ, Calderon-Rojas R, Dominguez AM, Cruz-Tapias P, et al. Usefulness of patients-reported outcomes in rheumatoid arthritis focus group. Arthritis. 2012;2012:935187.","journal-title":"Arthritis"},{"issue":"4","key":"3272_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11926-015-0501-8","volume":"17","author":"AM Orbai","year":"2015","unstructured":"Orbai AM, Bingham CO 3rd. Patient reported outcomes in rheumatoid arthritis clinical trials. Curr Rheumatol Rep. 2015;17(4):28.","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"3272_CR8","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1136\/annrheumdis-2011-201201","volume":"71","author":"SJ Bartlett","year":"2012","unstructured":"Bartlett SJ, Hewlett S, Bingham CO 3rd, Woodworth TG, Alten R, Pohl C, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis. 2012;71(11):1855\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3272_CR9","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1136\/ard.2008.100271","volume":"68","author":"L Gossec","year":"2009","unstructured":"Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadelo S, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis. 2009;68(11):1680\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3272_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/acr.20151","volume":"62","author":"T Sanderson","year":"2010","unstructured":"Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care Res (Hoboken). 2010;62(5):647\u201356.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"3272_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40271-014-0090-z","volume":"8","author":"SJ Coons","year":"2015","unstructured":"Coons SJ, Eremenco S, Lundy JJ, O\u2019Donohoe P, O\u2019Gorman H, Malizia W. Capturing patient-reported outcome (PRO) data electronically: the past, present, and promise of ePRO measurement in clinical trials. Patient. 2015;8(4):301\u20139.","journal-title":"Patient"},{"issue":"8","key":"3272_CR12","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s11136-011-0054-x","volume":"21","author":"CF Snyder","year":"2012","unstructured":"Snyder CF, Aaronson NK, Choucair AK, Elliott TE, Greenhalgh J, Halyard MY, et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012;21(8):1305\u201314.","journal-title":"Qual Life Res"},{"key":"3272_CR13","volume-title":"Paper vs. electronic diaries: compliance and subject evaluations","author":"MR Hufford","year":"2002","unstructured":"Hufford MR, Stone AA, Shiffman S, Schwartz JE, Broderick JE. Paper vs. electronic diaries: compliance and subject evaluations. 2002. \n                    http:\/\/alfresco.ubm-us.net\/alfresco_images\/pharma\/2014\/08\/22\/bb34ba55-e950-4531-8c08-aa1f3da6e0e3\/article-26823.pdf\n                    \n                  . Accessed 15 Aug 2017."},{"key":"3272_CR14","unstructured":"Guidance for Industry: computerized systems used in clinical investigations. Food and Drug Administration; 2007. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070266.pdf\n                    \n                  . Accessed 15 Aug 2017."},{"key":"3272_CR15","unstructured":"Guidance for Industry: electronic source data in clinical investigations. Food and Drug Administration; 2013. \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInform%20ation\/Guidances\/UCM328691.pdf\n                    \n                  . Accessed 15 Aug 2017."},{"issue":"4","key":"3272_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1524-4733.2008.00470.x","volume":"12","author":"SJ Coons","year":"2009","unstructured":"Coons SJ, Gwaltney CJ, Hays RD, Lundy JJ, Sloan JA, Revicki DA, et al. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health. 2009;12(4):419\u201329.","journal-title":"Value Health"},{"issue":"5","key":"3272_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jval.2014.06.005","volume":"17","author":"S Eremenco","year":"2014","unstructured":"Eremenco S, Coons SJ, Paty J, Coyne K, Bennett AV, McEntegart D, et al. PRO data collection in clinical trials using mixed modes: report of the ISPOR PRO Mixed Modes Good Research Practices Task Force. Value Health. 2014;17(5):501\u201316.","journal-title":"Value Health"},{"issue":"2","key":"3272_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1524-4733.2007.00231.x","volume":"11","author":"CJ Gwaltney","year":"2008","unstructured":"Gwaltney CJ, Shields AL, Shiffman S. Equivalence of electronic and paper-and-pencil administration of patient-reported outcome measures: a meta-analytic review. Value Health. 2008;11(2):322\u201333.","journal-title":"Value Health"},{"issue":"4","key":"3272_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jval.2013.04.002","volume":"16","author":"A Zbrozek","year":"2013","unstructured":"Zbrozek A, Hebert J, Gogates G, Thorell R, Dell C, Molsen E, et al. Validation of electronic systems to collect patient-reported outcome (PRO) data\u2014recommendations for clinical trial teams: report of the ISPOR ePRO Systems Validation Good Research Practices Task Force. Value Health. 2013;16(4):480\u20139.","journal-title":"Value Health"},{"issue":"3","key":"3272_CR20","first-page":"459","volume":"27","author":"F Salaffi","year":"2009","unstructured":"Salaffi F, Gasparini S, Grassi W. The use of computer touch-screen technology for the collection of patient-reported outcome data in rheumatoid arthritis: comparison with standardized paper questionnaires. Clin Exp Rheumatol. 2009;27(3):459\u201368.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"3272_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/msc.3","volume":"3","author":"S Hewlett","year":"2005","unstructured":"Hewlett S, Carr M, Ryan S, Kirwan J, Richards P, Carr A, et al. Outcomes generated by patients with rheumatoid arthritis: how important are they? Musculoskeletal Care. 2005;3(3):131\u201342.","journal-title":"Musculoskeletal Care"},{"key":"3272_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/03009742.2011.566433","volume":"125","author":"S Sierakowski","year":"2011","unstructured":"Sierakowski S, Cutolo M. Morning symptoms in rheumatoid arthritis: a defining characteristic and marker of active disease. Scand J Rheumatol Suppl. 2011;125:1\u20135.","journal-title":"Scand J Rheumatol Suppl"},{"issue":"2","key":"3272_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/1529-0131(200104)45:2<111::AID-ANR162>3.0.CO;2-E","volume":"45","author":"TP Suurmeijer","year":"2001","unstructured":"Suurmeijer TP, Waltz M, Moum T, Guillemin F, van Sonderen FL, Briancon S, et al. Quality of life profiles in the first years of rheumatoid arthritis: results from the EURIDISS longitudinal study. Arthritis Rheum. 2001;45(2):111\u201321.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"3272_CR24","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/rheumatology\/ken137","volume":"47","author":"G Westhoff","year":"2008","unstructured":"Westhoff G, Buttgereit F, Gromnica-Ihle E, Zink A. Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis. Rheumatology (Oxford). 2008;47(7):980\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3272_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88\u201395.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3272_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74(2):333\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3272_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12955-017-0813-7","volume":"15","author":"ED Bacci","year":"2017","unstructured":"Bacci ED, DeLozier AM, Lin CY, Gaich CL, Rooney T, Hoffman R, et al. Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis. Health Qual Life Outcomes. 2017;15(1):239.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"3272_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12955-017-0807-5","volume":"15","author":"ED Bacci","year":"2017","unstructured":"Bacci ED, DeLozier AM, Lin CY, Gaich CL, Zhang X, Rooney T, et al. Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis. Health Qual Life Outcomes. 2017;15(1):237.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"3272_CR29","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1524-4733.2008.00471.x","volume":"12","author":"D Wild","year":"2009","unstructured":"Wild D, Eremenco S, Mear I, Martin M, Houchin C, Gawlicki M, et al. Multinational trials\u2014recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force report. Value Health. 2009;12(4):430\u201340.","journal-title":"Value Health"},{"key":"3272_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0197-2456(02)00320-3","volume":"24","author":"AA Stone","year":"2003","unstructured":"Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient compliance with paper and electronic diaries. Control Clin Trials. 2003;24:182\u201399.","journal-title":"Control Clin Trials"},{"issue":"2","key":"3272_CR31","first-page":"69","volume":"22","author":"EB John","year":"2008","unstructured":"John EB. Electronic diaries: appraisal and current status. Pharmaceut Med. 2008;22(2):69\u201374.","journal-title":"Pharmaceut Med"},{"issue":"4","key":"3272_CR32","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ejpain.2008.05.010","volume":"13","author":"M Morren","year":"2009","unstructured":"Morren M, van Dulmen S, Ouwerkerk J, Bensing J. Compliance with momentary pain measurement using electronic diaries: a systematic review. Eur J Pain. 2009;13(4):354\u201365.","journal-title":"Eur J Pain"}],"updated-by":[{"DOI":"10.1186\/s13063-019-3463-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3272-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3272-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3272-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:14:43Z","timestamp":1584749683000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3272-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,22]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3272"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3272-0","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13063-019-3463-8","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,22]]},"assertion":[{"value":"13 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"After publication of the original article [1], the authors have notified us of an error in language used in the text:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was obtained from the human participants involved in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CB has served as a consultant to Eli Lilly and Company. PT has served as a consultant to Eli Lilly and Company and received research grant funding from Lilly. CG, AD, KE, SB, and AN are employees of Eli Lilly and Company, USA, and PB is an employee of Eli Lilly Services India Pvt. Ltd. CG, KE, SB, AN, and PB hold stock\/stock options at Eli Lilly and Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"182"}}